Emerging as a significant breakthrough in the fight against obesity, the drug is capturing considerable attention . This treatment combines the action of two recognized GLP-1 binding agonists, dulaglutide , plus an new glucose-dependent incretin component. Initial patient data have demonstrated impressive weight loss in people with a high BMI , … Read More